Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Nov 29, 2020 in Infertility | 0 comments

In a nutshell

This review looked at how often artificial gonadotropin hormones such as human follitropin alpha (Gonal-F) caused ovarian hyperstimulation syndrome (OHSS) or blood clots. It found that these conditions are infrequent side effects of using gonadotropins to stimulate the ovaries.

Some background

In a natural menstrual cycle, follicle-stimulating hormone (FSH) causes the ovarian follicles to develop. During ovulation, an oocyte (egg) is released from the follicle. FSH is part of a group of hormones known as gonadotropins. 

Gonadotropins are used during infertility treatment including in vitro fertilization (IVF). These hormones can be purified from the urine of menopausal women (Menopur). However, genetic engineering technology also allows for the production of gonadotropins. Recombinant FSH (r-FSH; Gonal-F) is a type of gonadotropin produced using hamster cells which is identical to human FSH.

High doses of gonadotropins are used during infertility treatment compared to a natural menstrual cycle, and this can have side effects. The ovaries sometimes respond too strongly to these medications, leading to swelling and discomfort. This condition is known as ovarian hyperstimulation syndrome (OHSS), and it can have serious complications. It is important to examine how often OHSS occurs when using r-FSH.

Methods & findings

This review included 45 studies of 5186 patients receiving r-FSH. The review also examined side effects reported to a German public health agency.

5.19% of r-FSH treatment cycles resulted in OHSS. Most of the studies (73.3%) classified whether the OHSS was severe. There were 10 reported cases of severe OHSS, which was 3.7% of all OHSS cases. There were no cases of blood clots in the studies.

The health agency received reports of 1110 cases of OHSS. This represents approximately 0.007% of r-FSH treatment cycles conducted in Germany during that time. The health agency also received 80 reports of blood clots.

The bottom line

This review found that blood clots and severe OHSS are unusual side effects of r-FSH.

The fine print

Most side effects in clinical practice are never reported to health agencies. However, these reports are useful to identify rare side effects which may not occur during clinical trials, such as blood clots.

Published By :

Advances in therapy

Date :

Oct 15, 2020

Original Title :

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.

click here to get personalized updates